What are the recommended management guidelines for dyspepsia?

Dyspepsia Management Guidelines

Initial Assessment and Risk Stratification

For patients presenting with dyspepsia, the management approach is determined primarily by age, with a critical threshold at 55-60 years, and the presence of alarm features.

Age-Based Endoscopy Thresholds

• Patients ≥55-60 years: Proceed directly to upper endoscopy to exclude malignancy and other organic pathology 1, 2
• Patients <55 years without alarm features: Pursue non-invasive H. pylori "test and treat" strategy 1, 2
• Exception: Consider endoscopy at younger ages for patients from high gastric cancer risk regions or with family history of gastroesophageal cancer 1, 2

Alarm Features Requiring Urgent Investigation

• Urgent endoscopy indicated for: Weight loss in patients ≥55 years, or age >40 years with family history of gastroesophageal cancer 1
• Urgent CT scanning: Consider in patients ≥60 years with abdominal pain AND weight loss to exclude pancreatic cancer 1
• Non-urgent endoscopy: Treatment-resistant dyspepsia, raised platelet count, or persistent nausea/vomiting in patients ≥55 years 1

Important caveat: Alarm features in younger patients (<55 years) should be evaluated case-by-case rather than automatically triggering endoscopy, as individual alarm symptoms have poor predictive value for malignancy in this age group 2, 3

Primary Care Management Algorithm for Patients <55 Years

Step 1: H. pylori Test and Treat Strategy

The "test and treat" approach is the recommended first-line strategy for young patients without alarm symptoms, as it identifies those at high risk for peptic ulcer disease while avoiding unnecessary endoscopy. 1

• Use non-invasive testing (urea breath test or stool antigen test preferred over serology) 1
• If positive, provide eradication therapy 1
• Confirmation of eradication is only necessary in patients at increased risk of gastric cancer 1
• This strategy cures peptic ulcer disease and eliminates ulcer-related mortality risk 1

Critical limitation: Many H. pylori-positive patients with functional dyspepsia will continue to have symptoms after successful eradication and require additional symptomatic therapy 1

Step 2: Empirical Acid Suppression for H. pylori-Negative or Persistent Symptoms

• First-line pharmacotherapy: Proton pump inhibitors (PPIs) at standard dose for 4-8 weeks 1, 2
• PPIs are superior to H2-receptor antagonists and placebo for symptom relief 1
• No dose-response benefit: Standard dose (e.g., omeprazole 20 mg daily) is as effective as higher doses 1, 4
• Continue at lowest effective dose if symptoms controlled 1

Functional Dyspepsia: Diagnosis and Subtyping

Diagnostic Criteria

Functional dyspepsia is diagnosed when patients have bothersome epigastric pain or burning, early satiation, and/or postprandial fullness for >8 weeks without structural explanation on endoscopy. 1

Rome IV Subtypes

• Epigastric Pain Syndrome (EPS): Predominant symptom is epigastric pain or burning 1, 4
• Postprandial Distress Syndrome (PDS): Predominant symptom is postprandial fullness, early satiation, or bloating 1, 4

Important note: Symptom subtyping has limited value for predicting underlying pathology in uninvestigated dyspepsia, but becomes useful for guiding treatment selection in confirmed functional dyspepsia 1

Treatment Algorithm for Functional Dyspepsia

First-Line Treatments

1. Lifestyle Modifications

• Regular aerobic exercise is strongly recommended 1
• Avoid foods that trigger symptoms 3
• Low-FODMAP diet may be considered but evidence is insufficient for routine recommendation 1, 3

2. H. pylori Eradication (if positive)

• Eradication therapy is efficacious even in functional dyspepsia, though many patients require additional treatment 1

3. Proton Pump Inhibitors

• PPIs are the most effective first-line pharmacotherapy for functional dyspepsia, particularly for EPS subtype 1, 4
• Use standard dose (e.g., omeprazole 20 mg daily) for 4-8 weeks 1, 2
• Most effective in patients with epigastric pain as predominant symptom 1
• Consider trial withdrawal after symptom control, with on-demand therapy for recurrence 1

4. Prokinetics

• Consider for PDS subtype with predominant fullness, bloating, or early satiety 1, 4
• Efficacy varies by agent; most effective agents (acotiamide, itopride, mosapride, tegaserod) have limited availability outside Asia/USA 1
• Do not use cisapride due to cardiac toxicity 1
• Not recommended as routine first-line therapy 4

Second-Line Treatments

1. Tricyclic Antidepressants (TCAs)

• TCAs are the most effective second-line treatment for functional dyspepsia refractory to PPIs 1, 2
• Start low (amitriptyline 10 mg once daily at bedtime) and titrate slowly to 30-50 mg daily 1
• Particularly effective for EPS subtype 4
• Continue for 6-12 months in responders 5
• Counsel patients extensively about rationale (gut-brain neuromodulation, NOT depression treatment) and side effects 1

2. Other Neuromodulators

• Mirtazapine: Recommended particularly for patients with weight loss 4
• Antipsychotics (sulpiride 100 mg four times daily or levosulpiride 25 mg three times daily): May be efficacious but use cautiously 1
• SSRIs: Insufficient evidence to recommend 4

Third-Line and Refractory Cases

1. Psychological Therapies

• Cognitive behavioral therapy is recommended for patients not responding to medical therapies 1, 4, 2
• Should be offered where available 5

2. Treatment Switching Strategy

• If first-choice therapy fails, consider switching drug classes (e.g., PPI to prokinetic or vice versa) as patients may have been misclassified by subtype 1
• Trial of high-dose PPI therapy may identify misclassified GORD patients 1

Specialist Referral and Advanced Management

Indications for Gastroenterology Referral

• Diagnostic uncertainty 1
• Severe or refractory symptoms despite first-line treatments 1
• Patient request for specialist opinion 1

Specialist Evaluation

• Review diagnosis to confirm functional dyspepsia is correct 1
• Perform endoscopy with gastric biopsies to document H. pylori status 1
• Consider 24-hour pH monitoring if atypical GORD suspected 1
• Do not routinely perform gastric emptying studies or pH monitoring in typical functional dyspepsia 1

Refractory Functional Dyspepsia Management

• Re-evaluate diagnosis 1
• Provide additional reassurance 1
• Consider behavioral therapy, psychotherapy, or antidepressants 1
• Trial visceral analgesic therapies in specialist setting 1

Key Distinctions: GORD vs Functional Dyspepsia

A critical management step is distinguishing GORD from functional dyspepsia, as they require different treatment approaches despite symptom overlap. 1

• GORD: Predominant symptom is heartburn 1
• Functional dyspepsia: Predominant symptom is epigastric pain or discomfort 1
• Validated heartburn questionnaires may improve identification 1
• Many patients have overlap of both conditions 1

Additional Testing Recommendations

• Full blood count: Perform in all patients ≥55 years 1
• Celiac serology: Perform in patients with overlapping IBS-type symptoms 1
• Do not routinely order: Abdominal ultrasound, motility studies, or extensive metabolic panels 4

Common Pitfalls to Avoid

1. Over-reliance on alarm features in young patients: Individual alarm symptoms have poor predictive value for malignancy in patients <55 years 2, 3

2. Empirical H. pylori eradication without testing: This causes overtreatment and is not recommended except in very high prevalence areas without testing access 1

3. Using symptom subgroups to predict organic disease: Symptom clusters (ulcer-like, reflux-like, dysmotility-like) do not reliably predict underlying pathology in uninvestigated dyspepsia 1

4. Inadequate patient education: Failure to explain functional dyspepsia as a disorder of gut-brain interaction leads to poor treatment adherence and continued healthcare utilization 1

5. Premature escalation to high-dose PPIs: Standard-dose PPIs are as effective as higher doses for functional dyspepsia 1, 4